Sun Pharmaceutical Industries Ltd and includes its subsidiaries and/or associate companies) has announced that it has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
source https://www.pharmatutor.org/pharma-news/2020/dcgi-approves-clinical-trial-of-sun-pharma-nafamostat-in-covid-19-patients
No comments:
Post a Comment